OBJECTIVE: Worldwide epidemiological studies have demonstrated that hepatitis C virus (HCV) probably is a causative agent of hepatocellular carcinoma (HCC). However, there are no available reports that clearly identify the risk factors for the development of HCC in HCV-related chronic liver disease (CLD). The aim of the present study is to explore the risk factors for hepatocarcinogenesis in HCV-related CLD. METHODS: We prospectively observed 412 patients with anti-HCV-positive CLD but without co-infection of hepatitis B virus (232 patients with chronic hepatitis and 180 with liver cirrhosis) for between 0.5 and 15.8 yr (median: 4.9 yr). Risk factors for hepatocarcinogenesis were identified with a Cox proportional-hazard model. RESULTS: Sixty-three patients (15.3%) developed HCC during the observation period; the cumulative occurrence rates at the end of the 5th, 10th, and 15th yr was 3.7%, 12.1%, and 12.1%, respectively, for chronic hepatitis patients and 23.3%, 49.4%, and 90.7%, respectively, for 180 cirrhotic patients. The Cox proportional-hazard model showed that the risk of hepatocarcinogenesis increased almost 5-fold in cirrhotic patients (risk ratio, 5.14; 95% confidence interval, 2.52-10.46, p = 0.0001), 2-fold in patients with positive antibodies against hepatitis B surface antigen and/or antibodies against hepatitis B core antigen (risk ratio, 2.14; 95% confidence interval, 1.13-4.07, p = 0.0201), and 2.5-fold in heavy smokers (risk ratio, 2.46; 95% confidence interval, 1.11-5.49, p = 0.0276). CONCLUSION: These epidemiological results indicate that previous infection with hepatitis B virus and heavy smoking (in addition to liver cirrhosis, a known risk factor) play important roles as risk factors for carcinogenesis in HCV-related CLD.
OBJECTIVE: Worldwide epidemiological studies have demonstrated that hepatitis C virus (HCV) probably is a causative agent of hepatocellular carcinoma (HCC). However, there are no available reports that clearly identify the risk factors for the development of HCC in HCV-related chronic liver disease (CLD). The aim of the present study is to explore the risk factors for hepatocarcinogenesis in HCV-related CLD. METHODS: We prospectively observed 412 patients with anti-HCV-positive CLD but without co-infection of hepatitis B virus (232 patients with chronic hepatitis and 180 with liver cirrhosis) for between 0.5 and 15.8 yr (median: 4.9 yr). Risk factors for hepatocarcinogenesis were identified with a Cox proportional-hazard model. RESULTS: Sixty-three patients (15.3%) developed HCC during the observation period; the cumulative occurrence rates at the end of the 5th, 10th, and 15th yr was 3.7%, 12.1%, and 12.1%, respectively, for chronic hepatitispatients and 23.3%, 49.4%, and 90.7%, respectively, for 180 cirrhotic patients. The Cox proportional-hazard model showed that the risk of hepatocarcinogenesis increased almost 5-fold in cirrhotic patients (risk ratio, 5.14; 95% confidence interval, 2.52-10.46, p = 0.0001), 2-fold in patients with positive antibodies against hepatitis B surface antigen and/or antibodies against hepatitis B core antigen (risk ratio, 2.14; 95% confidence interval, 1.13-4.07, p = 0.0201), and 2.5-fold in heavy smokers (risk ratio, 2.46; 95% confidence interval, 1.11-5.49, p = 0.0276). CONCLUSION: These epidemiological results indicate that previous infection with hepatitis B virus and heavy smoking (in addition to liver cirrhosis, a known risk factor) play important roles as risk factors for carcinogenesis in HCV-related CLD.
Authors: Amr S Soliman; Chu-Wei Hung; Alexander Tsodikov; Ibrahim A Seifeldin; Mohamed Ramadan; Dina Al-Gamal; Emily L Schiefelbein; Priyanka Thummalapally; Subhojit Dey; Kadry Ismail Journal: Hepatol Int Date: 2010-08-19 Impact factor: 6.047
Authors: S Kubo; A Tamori; K Ohba; T Shuto; T Yamamoto; H Tanaka; S Nishiguchi; K Wakasa; K Hirohashi; H Kinoshita Journal: Dig Dis Sci Date: 2001-11 Impact factor: 3.199
Authors: Francesca Lodato; Giuseppe Mazzella; Davide Festi; Francesco Azzaroli; Antonio Colecchia; Enrico Roda Journal: World J Gastroenterol Date: 2006-12-07 Impact factor: 5.742
Authors: Abdel Raouf Abou El Azm; Mohamed Yousef; Nagwa Mansour; Aymen Awad; Samia El Dardiry; Ibrahim Abdel Aziz Journal: J Gastrointest Cancer Date: 2014-09
Authors: H Marusawa; Y Osaki; T Kimura; K Ito; Y Yamashita; T Eguchi; M Kudo; Y Yamamoto; H Kojima; H Seno; F Moriyasu; T Chiba Journal: Gut Date: 1999-08 Impact factor: 23.059
Authors: Timothy M Pawlik; Ronnie T Poon; Eddie K Abdalla; Juan M Sarmiento; Iwao Ikai; Steven A Curley; David M Nagorney; Jacques Belghiti; Irene Oi-Lin Ng; Yoshio Yamaoka; Gregory Y Lauwers; Jean-Nicolas Vauthey Journal: J Gastrointest Surg Date: 2004-11 Impact factor: 3.452